Key takeaways:
- Nerva has acquired key assets of Mahana Therapeutics, a pioneer in digital therapies for chronic conditions backed by over $80 million in venture funding.
- IBS affects more than 11% of the population, and bodies like the AGA and ACG now recommend brain-gut behavioral therapies as part of high-quality care.
- Nerva will incorporate Mahana's proven cognitive behavioral therapy content to extend its existing psychoeducation and gut-directed hypnotherapy offering in the coming months.
- Clinicians who previously referred to Mahana are asked to transition to referring patients to Nerva through its secure, HIPAA-compliant online form.
Nerva, the world’s leading digital therapeutic for Irritable Bowel Syndrome (IBS), announced today that it has acquired key assets of Mahana Therapeutics, a pioneer in digital therapies for chronic conditions, including IBS.
Backed by over $80 million in venture funding, Mahana was foundational in establishing prescription digital therapeutics for digestive health. This strategic acquisition strengthens Nerva’s leadership in app-based brain-gut therapy and will accelerate its mission to deliver evidence-based, accessible care to the millions of patients living with IBS.
IBS is a complex disorder of gut-brain interaction (DGBI), affecting more than 11% of the population. Leading professional organisations, including the American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG), now recommend brain-gut behavioral therapies, such as gut-directed hypnotherapy and cognitive behavioral therapy, as part of a high-quality IBS care protocol. Recently, the AGA added digital therapeutics and gut-directed hypnotherapy
